A new report from STAT News on Gilead's experimental drug Remdesivir serves as an encouraging update on the drug's potential to fight Covid-19, however analysts argue it's largely anecdotal and should be interpreted with caution.
Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.
According to the report from an ongoing phase three trial at a University of Chicago hospital, patients showing severe Covid-19 symptoms who were given the drug saw rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than one week.
Gilead commented that, "the totality of the data need to be analysed in order to draw any conclusions from the trial," in a statement to Reuters. A statement from the University of Chicago Medicine said that "drawing any conclusions at this point is premature and scientifically unsound."
Jefferies equity analyst Michael J. Yee published in a research note that this Chicago report provides an "incremental positive" but he assumes this significant short-term move in Gilead's share price will probably pull back a bit given eventual broader awareness that this is not the actual phase three data and that this is overdone in the near term.
JPMorgan biotechnology equity analysts wrote in a published research note Thursday that "this clinical trial experience appears to represent another encouraging, albeit largely anecdotal, data point for this high-profile drug candidate."
Meanwhile, the Barclays health-care team called the update "encouraging" but note that questions persist.
The report from the Chicago hospital comes amid mounting anecdotal evidence supporting the drug's potential effectiveness in treating the virus. Last week, the New England Journal of Medicine published an analysis showing that two thirds of a small group of severely ill patients saw their condition improve after taking the drug. These patients were given Remdesivir as part of a compassionate use program which allows doctors to provide patients with unauthorized treatments when no other treatment is available.
There was no control group in the University of Chicago study. As CNBC's Meg Tirrell has highlighted, this is not controlled clinical trial data it is a glimpse into what one of the sites that is running the trial is seeing.
The information reported by STAT News came from an internal discussion among faculty members at a University of Chicago hospital captured on video, it was not official data released by Gilead or any other trial leader.
Furthermore, this data comes from a single trial site. The Barclays health-care equity research team wrote: "While these data are encouraging, they are uncontrolled and from a single center."
Jefferies echoes this point: "Similar to the NEJM publication last week, yesterday's reports are based on one site and there is no placebo."
There is also debate around the severity of the patients included in the study. This data is part of an ongoing phase three trial of patients with severe Covid-19 symptoms. However, the patients were not intubated to start the study. Barclays adds that there will be debate around the patient population and how they compare to past cohorts.
"There's still a great deal we don't know, and thus we hesitate to put too much into the results generated at a single center without a control group," said JPMorgan.
"Fortunately, we don't have to wait long for a Phase 3 readout in severe patients."
Gilead expects results from its trials with patients with severe Covid-19 later this month. Data from its trials on patients with moderate symptoms is expected in May.
In addition to these two trials being run by Gilead, there are several others underway concurrently to evaluate Remdesivir, including a phase two trial run by the National Institute of Health which is an adaptive, randomized, double-blind, placebo-controlled trial.
Barclays adds that data from Gilead's clinical trials on severe cases due at the end of this month could support approval or expanded use authorization. A treatment is not going to end the pandemic. But it will provide a critical bridge to the ultimate panacea a vaccine.
CNBC's Berkeley Lovelace contributed to this article.
Read more:
Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts say - CNBC
- Biotechnology Research Among Science Returned to Earth - ISS National Lab - May 5th, 2024
- Program to prepare next generation of biotech experts receives renewed funding - The University of Rhode Island - May 5th, 2024
- Designing drugs with reversible activity - Nature.com - May 5th, 2024
- ScienceLIVE helps answer 'What the Heck is Biotech?' for career-minded adults - UMass Medical School - May 5th, 2024
- Boston Micro Fabrication Launches BMF Biotechnology Inc. to Advance Use of 3D BioChips in Pharmaceutical and ... - Morningstar - May 5th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 - Business Wire - May 5th, 2024
- WuXi Biologics withdraws from 2024 BIO convention amid worsening geopolitical tensions - FiercePharma - May 5th, 2024
- Boston Micro Fabrication Launches BMF Biotechnology Inc. to Advance Use of 3D BioChips in Pharmaceutical and ... - Business Wire - May 5th, 2024
- U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033 - BioSpace - April 16th, 2024
- 6 biotechnology universities in the USA developing young talent - Labiotech.eu - April 16th, 2024
- Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - NBC Right Now - April 16th, 2024
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewswire - April 16th, 2024
- Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - pdclarion.com - April 16th, 2024
- BIO's top lobbyist heads out the door - FiercePharma - April 16th, 2024
- BIO's top lobbyist exits, signaling reorganization - STAT - STAT - April 16th, 2024
- Biotech Rebound Could Boost This ETF - ETF Trends - April 16th, 2024
- US National Security, China and Biotechnology in 2024 - BioSpace - April 8th, 2024
- How to Invest in Biotechnology (Updated 2024) - Nasdaq - April 8th, 2024
- Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression - Nature.com - April 8th, 2024
- Genetically encoding colors and images into bioengineered microbial materials - Nature.com - April 8th, 2024
- Ambition and urgency: Biotechnology and Biomanufacturing in the EU - EURACTIV - April 8th, 2024
- Scientists create plastic-free vegan leather that dyes itself, grown from bacteria - Phys.org - April 8th, 2024
- For national security, the U.S. must maintain its biotech dominance - STAT - April 8th, 2024
- LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside? - Yahoo Finance - April 8th, 2024
- Is biotechnology a good career? Here are the pros and cons - Labiotech.eu - March 18th, 2024
- Saving Biology With Blue Biotechnology - The Maritime Executive - March 18th, 2024
- 30 Biggest Biotechnology Companies in the World - Yahoo Finance - March 18th, 2024
- WuXi out of biotech trade group, U.S. and China relations to blame - STAT - March 18th, 2024
- Can Biotechnology Save the Fashion Industry? - EARTH.ORG - March 18th, 2024
- Huber high-precision temperature control solutions for the pharmaceutical industry and biotechnology - Labmate Online - March 18th, 2024
- The twelve hottest biotech companies in the Boston area - Labiotech.eu - March 18th, 2024
- Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes off - The Globe and Mail - March 10th, 2024
- Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation - Simply Wall St - March 10th, 2024
- The Top 25 Biotechnology Companies of 2024 - The Healthcare Technology Report. - March 10th, 2024
- Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature ... - Nature.com - March 10th, 2024
- MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain ... - Business Wire - March 10th, 2024
- Global Pharmaceuticals and Biotechnology Distribution Deals Analysis Report and Directory 2024: Breakdown of ... - PR Newswire - March 10th, 2024
- Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of ... - PR Newswire - March 10th, 2024
- INTERNATIONAL BIOTECHNOLOGY TRUST has a healthy attitude towards paying investors - This is Money - March 10th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Biotechnology should be high on the agenda at the Munich Security Conference - The Hill - February 18th, 2024
- Boston is best in the world at biotech. Beijing wants to do it better - WBUR News - February 18th, 2024
- Multiomics Are The Next Step In Biotechnology - Securities.io - February 18th, 2024
- SPARKing academic technologies across the valley of death - Nature.com - February 18th, 2024
- Is Nurix Therapeutics Inc (NRIX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Addressing the Threat to U.S. Biotechnology: Concerns Over Genetic Data Security - Medriva - February 18th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- Is Tempest Therapeutics Inc (TPST) a Leader in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Is Immunome Inc (IMNM) a Good Buy in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Is Larimar Therapeutics Inc (LRMR) a Leader in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- US lawmakers, visiting Cambridge, warn of a rising Chinese threat to US biotech - The Boston Globe - February 18th, 2024
- Should Biotechnology Stock Viking Therapeutics Inc (VKTX) Be in Your Portfolio Monday? - InvestorsObserver - February 18th, 2024
- How the push to limit Chinese biotech could threaten U.S. edge - Axios - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- BioAro Inc to Host Inaugural Longevity Innovation Forum in Dubai, UAE - Yahoo Finance - January 25th, 2024
- Is Akebia Therapeutics Inc (AKBA) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver - January 25th, 2024
- Agricultural Biotechnology Market Projected to Reach USD 64.7 billion, with Advancing CAGR of 9.5% by 2031 ... - Yahoo Finance - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- ZWI Therapeutics Announces Closing of $10M Series A Financing - FinSMEs - January 25th, 2024
- Breaking Barriers: Tiamat Sciences Shatters Norms with All-Female Executive Team - Yahoo Finance - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Is Cabaletta Bio Inc (CABA) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Why Investors and Media are Calling Biotech Showcase The Place to Be to Start the Year - Business Wire - January 25th, 2024
- Is IGC Pharma Inc (IGC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Is Summit Therapeutics Inc (SMMT) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Biotech Stocks: The Top 5 To Watch As Shares Trend Down - Investor's Business Daily - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- HRMY: Are These 3 Biotech Stocks Worth Buying? - StockNews.com - January 25th, 2024
- Global Preparative Chromatography Market is projected to reach US$ 2,139.4 Million by 2034 Amid Growing ... - Yahoo Finance - January 25th, 2024
- Is Immunome Inc (IMNM) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023